List of Inveltys drug patents
Inveltys is owned by Kala Pharms Inc.
Inveltys contains Loteprednol Etabonate.
Inveltys has a total of 10 drug patents out of which 0 drug patents have expired.
Inveltys was authorised for market use on 22 August, 2018.
Inveltys is available in suspension/drops;ophthalmic dosage forms.
Inveltys can be used as a method for delivering a composition to a mucus membrane, a method for treating inflammation and/or other disorders in an eye of a patient, a method for delivering a pharmaceutical agent across a mucosal barrier, a method for treating ocular inflammation, a method of reducing post-surgical pain following ocular surgery; a method of treating postoperative inflammation following ocular surgery.
The generics of Inveltys are possible to be released after 03 May, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9056057 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US9532955 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US10058511 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US11219597 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10864219 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US9737491 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US9827191 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10688045 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10646437 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US9393213 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 August, 2018
Treatment: A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; A method of reducing post-surgical pain following ocular surgery; A ...
Dosage: SUSPENSION/DROPS;OPHTHALMIC
INVELTYS family patents
36
United States
14
Japan
10
Australia
8
China
6
New Zealand
6
European Union
5
Canada
5
Korea, Republic of
4
Hong Kong
3
Mexico
3
Chile
1
Brazil
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic